Details of Drug

Drug General Information (ID: D1209)
Drug Name	Oxytetracycline
Drug Type	Small molecule
Drug Synonymous	Adamycin; Biostat; Dabicycline; Dalimycin; Fanterrin; Geomycin; Geotilin; Hydroxytetracycline; Imperacin; Lenocycline; Macocyn; OTC; Oksisyklin; Ossitetraciclina; Oxacycline; Oxitetraciclina; Oxitetracyclin; Oxitetracycline; Oxitetracyclinum; Oxymycin; Oxymykoin; Oxypam; Oxyterracin; Oxyterracine; Oxyterracyne; Oxytetracid; Oxytetracyclin; Oxytetracyclinum; Proteroxyna; Riomitsin; Ryomycin; Solkaciclina; Tarocyn; Tarosin; Teravit; Terrafungine; Terramitsin; Terramycin; Tetran; Unimycin; Ursocyclin; Ursocycline; Vendarcin; Biostat PA; Ossitetraciclina [DCIT]; Oxytetracycline HCl; Oxytetracycline [INN]; Oxytetracycline amphoteric; Oxytetracycline anhydrous; Oxytetracycline calcium; Terramycin im; Antibiotic TM 25; LA 200; Liquamycin LA 200; Mycoshield TMQTHC 20; Pennox 200; TM 5; Terramycin Q50; Geomycin (Streptomyces vimosus); OTC (antibiotic); Oxitetraciclina [INN-Spanish]; Oxytetracycline (anhydrous); Oxytetracycline (internal use); Oxytetracyclinum [INN-Latin]; Terramycin, Liquamycin, Oxytetracycline; (2E,4S,4aR,5S,5aR,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2E,4S,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (4S,4aR,5S,5aR,6S,12aS)-4-(dimethylamino)-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 5-Hydroxytetracycline Click to Show/Hide
Disease Class	1A00-1C4Z: Bacterial infection
Therapeutic Class	Antibiotics
Structure
Structure	3D Structure		2D Structure
Formula	C22H24N2O9
InChI	1S/C22H24N2O9/c1-21(32)7-5-4-6-8(25)9(7)15(26)10-12(21)17(28)13-14(24(2)3)16(27)11(20(23)31)19(30)22(13,33)18(10)29/h4-6,12-14,17,25-26,28,30,32-33H,1-3H3,(H2,23,31)/t12-,13-,14+,17+,21-,22+/m1/s1
InChIKey	OWFJMIVZYSDULZ-PXOLEDIWSA-N
Canonical SMILES	CC1(C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O)O
External Link
	Pubchem ID	54675779
	CAS Number	2058-46-0
	CHEBI ID	27701
	TTD ID	D0J2NK
	INTEDE ID	DR2697
	VARIDT ID	DR00635

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM001 Affected gastrointestinal absorption AM003 Affected organization distribution AM004 Affected intra/extra-hepatic metabolism AM005 Affected excretion pathways AM006 Pharmacodynamic additive effects AM007 Pharmacodynamic antagonistic effects BM002 Altered intestinal flora BM003 Complex formation BM004 Adsorption BM013 Competitive binding of plasma proteins BM014 Interference of cell/tissue uptake BM017 CYP450 enzyme inhibition BM029 Altered urine pH BM045 Additive neuromuscular blocking effects BM055 Increased risk of hepatotoxicity BM064 Increased risk of hypoglycemia BM072 Increased risk of nephrotoxicity BM075 Increased risk of photosensitivity reactions BM077 Increased risk of pseudotumor cerebri BM100 Antagonize the effect of vaccine/toxoid BM107 Attenuated pharmacological effects (Unspecific)
Relation Graph

Full list of drugs interacting with Oxytetracycline
Affected gastrointestinal absorption
	Altered intestinal flora					Drug Num: 3
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0491		Digoxin	C41H64O14	2724385	Moderate		Inter Info	[46], [47], [48], [49]
D1094		Mycophenolate mofetil	C23H31NO7	5281078	Moderate		Inter Info	[117], [118]
D1095		Mycophenolic acid	C17H20O6	446541	Moderate		Inter Info	[117], [118]
	Complex formation					Drug Num: 35
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0235		Calcium acetate	C4H6CaO4	6116	Moderate		Inter Info	[32], [33], [34], [35], [36], [37], [38], [39], [40], [10], [41], [42], [43]
D0240		Calcium glucoheptonate	C14H26CaO16	62859	Moderate		Inter Info	[35], [38], [42]
D0049		Aluminum hydroxide	AlH3O3	10176082	Moderate		Inter Info	[32], [33], [34], [35], [36], [37], [38], [39], [40], [10], [41], [42], [43]
D0186		Bismuth subgallate	C7H6BiO6	16682999	Moderate		Inter Info	[86], [87], [40]
D0187		Bismuth subsalicylate	C7H6BiO4	16682734	Moderate		Inter Info	[86], [87], [40], [10]
D0236		Calcium carbonate	CCaO3	10112	Moderate		Inter Info	[35], [38], [42]
D0237		Calcium chloride	CaCl2H4O2	24844	Moderate		Inter Info	[32], [33], [34], [35], [36], [37], [38], [39], [40], [10], [41], [42], [43]
D0238		Calcium citrate	C12H10Ca3O14	13136	Moderate		Inter Info	[32], [33], [34], [35], [36], [37], [38], [39], [40], [10], [41], [42], [43]
D0239		Calcium glubionate anhydrous	C18H32CaO19	64776	Moderate		Inter Info	[35], [38], [42]
D0241		Calcium gluconate	C12H22CaO14	9290	Moderate		Inter Info	[32], [33], [34], [35], [36], [37], [38], [39], [40], [10], [41], [42], [43]
D0243		Calcium lactate	C6H10CaO6	13144	Moderate		Inter Info	[32], [33], [34], [35], [36], [37], [38], [39], [40], [10], [41], [42], [43]
D0244		Calcium Phosphate	Ca3O8P2	24456	Moderate		Inter Info	[35], [38], [42]
D0619		Ethinylestradiol	C20H24O2	5991	Moderate		Inter Info	[99], [100], [101]
D0649		Ferrous fumarate	C4H2FeO4	6433164	Moderate		Inter Info	[102], [103], [104], [105], [37], [106], [107], [108], [40], [10], [109]
D0650		Ferrous gluconate	C12H22FeO14	23616740	Moderate		Inter Info	[102], [103], [104], [105], [37], [106], [107], [108], [40], [10], [109]
D0651		Ferrous sulfate anhydrous	FeO4S	24393	Moderate		Inter Info	[103], [104], [40]
D0847		Iron	Fe	23925	Moderate		Inter Info	[103], [104], [40]
D0850		Iron sucrose	C12H29Fe5Na2O23	91663255	Moderate		Inter Info	[37], [40], [112]
D0877		Kaolin	Al2H4O9Si2	56841936	Moderate		Inter Info	[35], [38], [42]
D0893		Lanthanum carbonate	C3La2O9	168924	Moderate		Inter Info	[53], [5], [20], [116], [40], [10]
D0968		Magnesium carbonate	CMgO3	11029	Moderate		Inter Info	[35], [38], [42]
D0969		Magnesium chloride	Cl2H12MgO6	643991	Moderate		Inter Info	[32], [33], [34], [35], [36], [37], [38], [39], [40], [10], [41], [42], [43]
D0970		Magnesium citrate	C12H10Mg3O14	6099959	Moderate		Inter Info	[32], [33], [34], [35], [36], [37], [38], [39], [40], [10], [41], [42], [43]
D0971		Magnesium gluconate	C12H22MgO14	11418570	Moderate		Inter Info	[32], [33], [34], [35], [36], [37], [38], [39], [40], [10], [41], [42], [43]
D0973		Magnesium hydroxide	H2MgO2	14791	Moderate		Inter Info	[32], [33], [34], [35], [36], [37], [38], [39], [40], [10], [41], [42], [43]
D0974		Magnesium oxide	MgO	14792	Moderate		Inter Info	[32], [33], [34], [35], [36], [37], [38], [39], [40], [10], [41], [42], [43]
D0975		Magnesium sulfate	MgO4S	24083	Moderate		Inter Info	[32], [33], [34], [35], [36], [37], [38], [39], [40], [10], [41], [42], [43]
D1011		Mestranol	C21H26O2	6291	Moderate		Inter Info	[99], [100], [101]
D1369		Quinapril	C25H30N2O5	54892	Moderate		Inter Info	[20], [40], [10]
D1566		Tetraferric tricitrate decahydrate	C18H32Fe4O31	90478690	Moderate		Inter Info	[124], [40], [10]
D1722		Zinc acetate	C4H6O4Zn	11192	Moderate		Inter Info	[104], [37], [125], [40], [10]
D1723		Zinc chloride	Cl2Zn	5727	Moderate		Inter Info	[37], [40], [10]
D1724		Zinc gluconate	C12H22O14Zn	443445	Moderate		Inter Info	[104], [37], [125], [40], [10]
D1725		Zinc sulfate	O4SZn	24424	Moderate		Inter Info	[104], [37], [125], [40], [10]
D0382		Colestipol	C11H28ClN5O	62816	Minor		Inter Info	[129], [130], [131]
	Adsorption					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0021		Activated charcoal	C	5462310	Moderate		Inter Info	[59], [60], [61], [62], [63], [64], [65], [66], [67], [68], [69], [70], [71], [72], [73], [74], [75], [76], [77], [78], [79], [80], [81], [82], [83]
Affected organization distribution
	Competitive binding of plasma proteins					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1025		Methotrexate	C20H22N8O5	126941	Moderate		Inter Info	[53], [5], [20], [54], [55]
	Interference of cell/tissue uptake					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1817		Indium In-111 oxyquinoline	C27H18InN3O3	16685037	Moderate		Inter Info	[111]
Affected intra/extra-hepatic metabolism
	CYP450 enzyme inhibition					Drug Num: 2
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0064		Aminophylline	C16H24N10O4	9433	Moderate		Inter Info	[35], [36], [42]
D1570		Theophylline	C7H8N4O2	2153	Moderate		Inter Info	[35], [36], [42]
Affected excretion pathways
	Altered urine pH					Drug Num: 6
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0886		Lactic acid	C3H6O3	612	Moderate		Inter Info	[113], [114], [115]
D1319		Potassium citrate	C6H5K3O7	13344	Moderate		Inter Info	[113], [114], [115]
D1478		Sodium acetate	C2H3NaO2	517045	Moderate		Inter Info	[113], [114], [115]
D1480		Sodium bicarbonate	CHNaO3	516892	Moderate		Inter Info	[113], [114], [115]
D1483		Sodium citrate	C6H5Na3O7	6224	Moderate		Inter Info	[113], [114], [115]
D1654		Tromethamine	C4H11NO3	6503	Moderate		Inter Info	[113], [114], [115]
Pharmacodynamic additive effects
	Additive neuromuscular blocking effects					Drug Num: 7
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0343		Cisatracurium	C53H72N2O12+2	62887	Moderate		Inter Info	[44], [45]
D0122		Atracurium	C53H72N2O12+2	47319	Moderate		Inter Info	[44], [45]
D1080		Mivacurium	C58H80N2O14+2	5281042	Moderate		Inter Info	[44], [45]
D1219		Pancuronium	C35H60N2O4+2	441289	Moderate		Inter Info	[44], [45]
D1420		Rocuronium	C32H53N2O4+	441290	Moderate		Inter Info	[44], [45]
D1684		Vecuronium	C34H57N2O4+	39765	Moderate		Inter Info	[44], [45]
D1510		Succinylcholine	C14H30N2O4+2	5314	Moderate		Inter Info	[44], [45]
	Increased risk of hepatotoxicity					Drug Num: 8
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0944		Lomitapide	C39H37F6N3O2	9853053	Major		Inter Info	[24]
D1073		Mipomersen	C230H324N67O122P19S19	118984467	Major		Inter Info	[25]
D1258		Pexidartinib	C20H15ClF3N5	25151352	Major		Inter Info	[26]
D0149		Bedaquiline	C32H31BrN2O2	5388906	Moderate		Inter Info	[85]
D0232		Calaspargase pegol	NA	NA	Moderate		Inter Info	[88], [89], [90], [5], [20], [91], [92], [93], [94], [95], [96], [97], [98]
D0789		Idelalisib	C22H18FN7O	11625818	Moderate		Inter Info	[110]
D1389		Remdesivir	C27H35N6O8P	121304016	Moderate		Inter Info	[5], [20], [121], [122], [123]
D1234		Pegaspargase	C14H19NO	436058	Moderate		Inter Info	[88], [89], [90], [5], [20], [91], [92], [93], [94], [95], [96], [97], [98]
	Increased risk of hypoglycemia					Drug Num: 11
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0811		Insulin glargine	C267H404N72O78S6	118984454	Moderate		Inter Info	[50], [51], [52]
D0814		Insulin human (inhalation, rapid acting)	C257H383N65O77S6	118984375	Moderate		Inter Info	[50], [51], [52]
D0815		Insulin human (isophane)	C257H383N65O77S6	118984375	Moderate		Inter Info	[50], [51], [52]
D0816		Insulin human (regular)	C257H383N65O77S6	118984375	Moderate		Inter Info	[50], [51], [52]
D0817		Insulin human (zinc extended)	C257H383N65O77S6	118984375	Moderate		Inter Info	[50], [51], [52]
D0818		Insulin human (zinc)	C257H383N65O77S6	118984375	Moderate		Inter Info	[50], [51], [52]
D0819		Insulin lispro	C257H389N65O77S6	16132438	Moderate		Inter Info	[50], [51], [52]
D0808		Insulin aspart (aspart)	C256H381N65O79S6	118984445	Moderate		Inter Info	[50], [51], [52]
D0809		Insulin degludec	C274H411N65O81S6	118984462	Moderate		Inter Info	[50], [51], [52]
D0810		Insulin detemir	C267H402N64O76S6	16137271	Moderate		Inter Info	[50], [51], [52]
D0812		Insulin glulisine	C258H384N64O78S6	16136701	Moderate		Inter Info	[50], [51], [52]
	Increased risk of nephrotoxicity					Drug Num: 19
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0058		Amiloride	C6H8ClN7O	16231	Minor		Inter Info	[34], [127], [128]
D0326		Chlorthalidone	C14H11ClN2O4S	2732	Minor		Inter Info	[34], [127], [128]
D1048		Metolazone	C16H16ClN3O3S	4170	Minor		Inter Info	[34], [127], [128]
D0012		Acetazolamide	C4H6N4O3S2	1986	Minor		Inter Info	[34], [127], [128]
D0217		Bumetanide	C17H20N2O5S	2471	Minor		Inter Info	[34], [127], [128]
D0321		Chlorothiazide	C7H6ClN3O4S2	2720	Minor		Inter Info	[34], [127], [128]
D0479		Diclofenamide	C6H6Cl2N2O4S2	3038	Minor		Inter Info	[34], [127], [128]
D0613		Etacrynic acid	C13H12Cl2O4	3278	Minor		Inter Info	[34], [127], [128]
D0704		Furosemide	C12H11ClN2O5S	3440	Minor		Inter Info	[34], [127], [128]
D0731		Glycerin	C3H8O3	753	Minor		Inter Info	[34], [127], [128]
D0771		Hydrochlorothiazide	C7H8ClN3O4S2	3639	Minor		Inter Info	[34], [127], [128]
D0775		Hydroflumethiazide	C8H8F3N3O4S2	3647	Minor		Inter Info	[34], [127], [128]
D0798		Indapamide	C16H16ClN3O3S	3702	Minor		Inter Info	[34], [127], [128]
D0978		Mannitol	C6H14O6	6251	Minor		Inter Info	[34], [127], [128]
D1018		Methazolamide	C5H8N4O3S2	4100	Minor		Inter Info	[34], [127], [128]
D1311		Polythiazide	C11H13ClF3N3O4S3	4870	Minor		Inter Info	[34], [127], [128]
D1501		Spironolactone	C24H32O4S	5833	Minor		Inter Info	[34], [127], [128]
D1611		Torasemide	C16H20N4O3S	41781	Minor		Inter Info	[34], [127], [128]
D1631		Triamterene	C12H11N7	5546	Minor		Inter Info	[34], [127], [128]
	Increased risk of photosensitivity reactions					Drug Num: 5
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1028		Methoxsalen	C12H8O4	4114	Moderate		Inter Info	[5], [44], [56], [57], [58]
D0063		Aminolevulinic acid (topical)	C5H9NO3	137	Moderate		Inter Info	[5], [20], [84]
D1033		Methyl aminolevulinate (topical)	C6H11NO3	157922	Moderate		Inter Info	[5], [20], [84]
D1314		Porfimer sodium	C68H74N8O11	135577896	Moderate		Inter Info	[119], [20], [120]
D1691		Verteporfin	C82H84N8O16	11980904	Moderate		Inter Info	[20], [44], [56], [126]
	Increased risk of pseudotumor cerebri					Drug Num: 4
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0018		Acitretin	C21H26O3	5284513	Major		Inter Info	[1], [2], [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23]
D0863		Isotretinoin	C20H28O2	5282379	Major		Inter Info	[1], [2], [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23]
D1626		Tretinoin	C20H28O2	444795	Major		Inter Info	[1], [2], [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23]
D1702		Vitamin A	C20H30O	445354	Major		Inter Info	[9], [14], [12], [10], [13], [11], [22], [16], [15], [17], [18], [23], [8], [2], [4], [7], [19], [5], [20], [1], [3], [6], [21]
Pharmacodynamic antagonistic effects
	Antagonize the effect of vaccine/toxoid					Drug Num: 2
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1914		Typhoid vaccine (live)	NA	NA	Major		Inter Info	[20], [27], [28]
D1693		Vibrio cholerae CVD 103-HgR strain live antigen (live)	NA	NA	Major		Inter Info	[29]
	Attenuated pharmacological effects (Unspecific)					Drug Num: 12
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0079		Ampicillin	C16H19N3O4S	6249	Moderate		Inter Info	[10], [30], [31]
D0257		Carbenicillin	C17H18N2O6S	20824	Moderate		Inter Info	[10], [30], [31]
D0480		Dicloxacillin	C19H17Cl2N3O5S	18381	Moderate		Inter Info	[10], [30], [31]
D0073		Amoxicillin	C16H19N3O5S	33613	Moderate		Inter Info	[10], [30], [31]
D0167		Benzylpenicillin	C16H18N2O4S	5904	Moderate		Inter Info	[10], [30], [31]
D0168		Benzylpenicillin (potassium)	C16H18N2O4S	5904	Moderate		Inter Info	[10], [30], [31]
D0169		Benzylpenicillin (sodium)	C16H18N2O4S	5904	Moderate		Inter Info	[10], [30], [31]
D1099		Nafcillin	C21H22N2O5S	8982	Moderate		Inter Info	[10], [30], [31]
D1192		Oxacillin	C19H19N3O5S	6196	Moderate		Inter Info	[10], [30], [31]
D1580		Ticarcillin	C15H16N2O6S2	36921	Moderate		Inter Info	[10], [30], [31]
D1268		Phenoxymethylpenicillin	C16H18N2O5S	6869	Moderate		Inter Info	[10], [30], [31]
D1296		Piperacillin	C23H27N5O7S	43672	Moderate		Inter Info	[10], [30], [31]

References
1	Gardner K, Cox T, Digre KB "Idiopathic intracranial hypertension associated with tetracycline use in fraternal twins: case reports and review." Neurology 45 (1995): 6-10. [PMID: 7824136]
2	Chan AY, Liu DT, Friedman DI, Gordon LK, Egan RA "Doxycycline and intracranial hypertension." Neurology 64 (2005): 765-6. [PMID: 15728321]
3	Walters BN, Gubbay SS "Tetracycline and benign intracranial hypertension: report of five cases." Br Med J 282 (1981): 19-20. [PMID: 6449976]
4	Donnet A, Dufour H, Graziani N, Grisoli F "Minocycline and benign intracranial hypertension." Biomed Pharmacother 46 (1992): 171-2. [PMID: 1421048]
5	Cerner Multum, Inc. "Australian Product Information.".
6	Yokokura M, Hatake K, Komatsu N, Kajitani H, Miura Y "Toxicity of tretinoin in acute promyelocytic leukaemia." Lancet 343 (1994): 361-2. [PMID: 7905175]
7	Product Information. Achromycin (tetracycline). Lederle Laboratories, Wayne, NJ.
8	Chiu AM, Chuenkongkaew WL, Cornblath WT, Trobe JD, Digre KB, Dotan SA, Musson KH, Eggenberger ER "Minocycline treatment and pseudotumor cerebri syndrome." Am J Ophthalmol 126 (1998): 116-21. [PMID: 9683157]
9	Lewis PA, Kearney PJ "Pseudotumor cerebri induced by minocycline treatment for acne vulgaris." Acta Derm Venereol 77 (1997): 83. [PMID: 9059695]
10	Product Information. Seysara (sarecycline). Allergan Inc, Irvine, CA.
11	Lee AG "Pseudotumor cerebri after treatment with tetracycline and isotretinoin for acne." Cutis 55 (1995): 165-8. [PMID: 7634848]
12	Product Information. Accutane (isotretinoin). Roche Laboratories, Nutley, NJ.
13	Tabibian JH, Gutierrez MA "Doxycycline-induced pseudotumor cerebri." South Med J 102 (2009): 310-1. [PMID: 19204639]
14	Cuddihy J "Case report of benign intercranial hypertension secondary to tetracycline." Ir Med J 87 (1994): 90. [PMID: 8056550]
15	Minutello JS, Dimayuga RG, Carter J "Pseudotumor cerebri, a rare adverse reaction to tetracycline therapy." J Periodontol 59 (1988): 848-51. [PMID: 3225732]
16	Roytman M, Frumkin A, Bohn TG "Pseudotumor cerebri caused by isotretinoin." Cutis 42 (1988): 399-400. [PMID: 2973971]
17	Product Information. Soriatane (acitretin). Roche Laboratories, Nutley, NJ.
18	Delaney RA, Narayanaswamy TR "Pseudo-tumor cerebri and acne." Mil Med 155 (1990): 511. [PMID: 2146526]
19	Moskowitz Y, Leibowitz E, Ronen M, Aviel E "Pseudotumor cerebri induced by vitamin A combined with minocycline." Ann Ophthalmol 25 (1993): 306-8. [PMID: 8239326]
20	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
21	Weese-Mayer DE, Yang RJ, Mayer JR, Zaparackas Z "Minocycline and Pseudotumor cerebri: The well-known but well-kept secret." Pediatrics 108 (2001): 519-20. [PMID: 11491116]
22	Product Information. Vesanoid (tretinoin). Roche Laboratories, Nutley, NJ.
23	Schmitt K, Schwarz R, Tulzer G, Krieger O, Zoubek A, Gadner H "Toxicity of tretinoin in acute promyelocytic leukaemia." Lancet 343 (1994): 361. [PMID: 7905174]
24	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
25	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
26	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
27	UK government "Typhoid.".
28	American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association (1994).
29	Product Information. Vaxchora (cholera vaccine, live). PaxVax, Miami, FL.
30	Jawetz E "Synergism and antagonism among antimicrobial drugs: a personal perspective." West J Med 123 (1975): 87-91
31	Olsson RA, Kirby JC, Romansky MJ "Pneumococcal meningitis in the adult." Ann Intern Med 55 (1961): 545-9
32	Covington TR, Lawson LC, Young LL, eds. "Handbook of Nonprescription Drugs. 10th ed." Washington, DC: American Pharmaceutical Association (1993):.
33	D'Arcy PF, McElnay JC "Drug-antacid interactions: assessment of clinical importance." Drug Intell Clin Pharm 21 (1987): 607-17. [PMID: 2886325]
34	Garty M, Hurwitz A "Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline." Clin Pharmacol Ther 28 (1980): 203-7. [PMID: 7398187]
35	Gotz VP, Ryerson GG "Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease." Drug Intell Clin Pharm 20 (1986): 694-6. [PMID: 3757782]
36	McCormack JP, Reid SE, Lawson LM "Theophylline toxicity induced by tetracycline." Clin Pharm 9 (1990): 546-9. [PMID: 2376112]
37	Neuvonen PJ "Interactions with the absorption of tetracyclines." Drugs 11 (1976): 45-54. [PMID: 946598]
38	Nguyen VX, Nix DE, Gillikin S, Schentag JJ "Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline." Antimicrob Agents Chemother 33 (1989): 434-6. [PMID: 2729939]
39	Product Information. Declomycin (demeclocycline). Lederle Laboratories, Wayne, NJ.
40	Product Information. Nuzyra (omadacycline). Paratek Pharmaceuticals, Inc., Boston, MA.
41	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
42	Upton RA "Pharmacokinetic interactions between theophylline and other medication (Part I)." Clin Pharmacokinet 20 (1991): 66-80. [PMID: 1674242]
43	Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7. [PMID: 2610502]
44	Multum Information Services, Inc. Expert Review Panel.
45	Product Information. Anectine (succinylcholine). Glaxo Wellcome, Research Triangle Park, NC.
46	Lindenbaum J, Rund DG, Butler VP Jr, Tse-Eng D, Saha JR "Inactivation of digoxin by the gut flora: reversal by antibiotic therapy." N Engl J Med 305 (1981): 789-94. [PMID: 7266632]
47	Lindenbaum J, Tse-Eng D, Butler VP, Rund DG "Urinary excretion of reduced metabolites of digoxin." Am J Med 71 (1981): 67-74. [PMID: 7246583]
48	Product Information. Lanoxicaps (digoxin). Glaxo Wellcome, Research Triangle Park, NC.
49	Rodin SM, Johnson BF "Pharmacokinetic interactions with digoxin." Clin Pharmacokinet 15 (1988): 227-44. [PMID: 3056649]
50	Miller JB "Hypoglycaemic effect of oxytetracycline." BMJ 2 (1966): 1007
51	Begin-Heick N, Heick HM, Norman MG "Regranulation of Islets of Langerhans and normalization of in vivo insulin secretion in ob/ob mice treated with oxytetracycline." Diabetes 28 (1979): 65-70
52	Dalpe-Scott M, Heick HM, Begin-Heick N "Insulin secretion in the obese (ob/ob) mouse: the effect of oxytetracycline on insulin release." Diabetes 32 (1983): 932-7
53	Canadian Pharmacists Association.
54	Product Information. Methotrexate (methotrexate). Lederle Laboratories, Wayne, NJ.
55	Tortajada-Ituren JJ, Ordovas-Baines JP, Llopis-Salvia P, Jimenez-Torres NV "High-dose methotrexate-doxycycline interaction." Ann Pharmacother 33 (1999): 804-8. [PMID: 10466909]
56	Product Information. Nulibry (fosdenopterin). Origin Biosciences Inc, Boston, MA.
57	Product Information. Oxsoralen (methoxsalen). ICN Pharmaceuticals Inc, Costa Mesa, CA.
58	Product Information. Uvadex (methoxsalen). Therakos Inc, Exton, PA.
59	Bonuccelli U, Piccini P, Del Dotto P, Pavese N, D'Antonio P, Muratorio A "Apomorphine test in de novo Parkinson's disease." Funct Neurol 7 (1992): 295-8. [PMID: 1427361]
60	Chernish SM, Wolen RL, Rodda BE "Adsorption of propoxyphene hydrochloride by activated charcoal." Clin Toxicol 5 (1972): 317-29. [PMID: 5073815]
61	Decker WJ, Shpall RA, Corby DG "Inhibition of aspirin absorption by activated charcoal and apomorphine." Clin Pharmacol Ther 10 (1969): 710-3. [PMID: 5808464]
62	Dolgin JG, Nix DE, Sanchez J, Watson WA "Pharmacokinetic simulation of the effect of multiple-dose activated charcoal in phenytoin poisoning: report of two pediatric cases." DICP 25 (1991): 646-9. [PMID: 1877275]
63	Farrar HC, Herold DA, Reed MD "Acute valproic acid intoxication: enhanced drug clearance with oral-activated charcoal." Crit Care Med 21 (1993): 299-301. [PMID: 8428486]
64	Gadgil SD, Damle SR, Advani SH, Vaidya AB "Effect of activated charcoal on the pharmacokinetics of high-dose methotrexate." Cancer Treat Rep 66 (1982): 1169-71. [PMID: 7083219]
65	Glab WN, Corby DG, Decker WJ, Coldiron VR "Decreased absorption of propoxyphene by activated charcoal." J Toxicol Clin Toxicol 19 (1982): 129-38. [PMID: 6125599]
66	Herrington AM, Clifton GD "Toxicology and management of acute drug ingestions in adults." Pharmacotherapy 15 (1995): 182-200. [PMID: 7624266]
67	Howard CE, Roberts RS, Ely DS, Moye RA "Use of multiple-dose activated charcoal in phenytoin toxicity." Ann Pharmacother 28 (1994): 201-3. [PMID: 8173135]
68	Ilkhanipour K, Yealy DM, Krenzelok EP "Activated charcoal surface area and its role in multiple-dose charcoal therapy." Am J Emerg Med 11 (1993): 583-5. [PMID: 8240556]
69	Karkkainen S, Neuvonen PJ "Effect of oral charcoal and urine pH on dextropropoxyphene pharmacokinetics." Int J Clin Pharmacol Ther Toxicol 23 (1985): 219-25. [PMID: 2987139]
70	Kivisto KT, Neuvonen PJ "The effect of cholestyramine and activated charcoal on glipizide absorption." Br J Clin Pharmacol 30 (1990): 733-6. [PMID: 2271372]
71	Knadler MP, Bergstrom RF, Callaghan JT, Obermeyer BD, Rubin A "Absorption studies of the H2-blocker nizatidine." Clin Pharmacol Ther 42 (1987): 514-20. [PMID: 2890459]
72	Naveau S, Bonhomme L, Preaux N, Chaput JC "A pure charcoal suspension for colonoscopic tattoo." Gastrointest Endosc 37 (1991): 624-5. [PMID: 1756921]
73	Neuvonen PJ "Clinical pharmacokinetics of oral activated charcoal in acute intoxications." Clin Pharmacokinet 7 (1982): 465-89. [PMID: 6761032]
74	Orisakwe OE "Activated charcoal: is failure to use it negligence or ignorance?" South Med J 87 (1994): 165-8. [PMID: 8115876]
75	Park GD, Spector R, Goldberg MJ, Johnson GF "Expanded role of charcoal therapy in the poisoned and overdosed patient." Arch Intern Med 146 (1986): 969-73. [PMID: 3516107]
76	Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
77	Reed MD "Oral activated charcoal therapy." Am J Emerg Med 6 (1988): 318. [PMID: 3370115]
78	Rowden AM, Spoor JE, Bertino JS, Jr "The effect of activated charcoal on phenytoin pharmacokinetics." Ann Emerg Med 19 (1990): 1144-7. [PMID: 2221521]
79	Saetta JP "Gastric decontaminating procedures: is it time to call a stop?" J R Soc Med 86 (1993): 396-9. [PMID: 8371247]
80	Scheufler E, Bos I "Influence of peroral charcoal on pharmacokinetics and intestinal toxicity of intravenously given methotrexate." Arch Int Pharmacodyn Ther 261 (1983): 180-5. [PMID: 6838279]
81	Wakabayashi Y, Maruyama S, Hachimura K, Ohwada T "Activated charcoal interrupts enteroenteric circulation of phenobarbital." J Toxicol Clin Toxicol 32 (1994): 419-24. [PMID: 8057401]
82	Watson WA "Factors influencing the clinical efficacy of activated charcoal." Drug Intell Clin Pharm 21 (1987): 160-6. [PMID: 3549212]
83	Wing LM, Miners JO, Birkett DJ, et al "Lidocaine disposition: sex differences and effects of cimetidine." Clin Pharmacol Ther 35 (1984): 695-701. [PMID: 6713782]
84	Product Information. Metvixia (methyl aminolevulinate topical). Galderma Laboratories Inc, Cranbury, NJ.
85	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
86	Albert KS, Welch RD, DeSante KA, DiSanto AR "Decreased tetracycline bioavailability caused by a bismuth subsalicylate antidiarrheal mixture." J Pharm Sci 68 (1979): 586-8. [PMID: 435335]
87	Ericsson CD, Feldman S, Pickering LK, Cleary TG "Influence of subsalicylate bismuth on absorption of doxycycline." JAMA 247 (1982): 2266-7. [PMID: 7040708]
88	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
89	Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krahenbuhl S "Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase." Digestion 74 (2006): epub. [PMID: 16988508]
90	Cerner Multum, Inc "ANVISA Bulario Eletrnico.".
91	Christ TN, Stock W, Knoebel RW "Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen." J Oncol Pharm Pract 24 (2018): 299-308. [PMID: 28355969]
92	Jenkins R, Perlin E "Severe hepatotoxicity from Escherichia coli L-asparaginase." J Natl Med Assoc 79 (1987): 775-9. [PMID: 3305969]
93	Lu G, Karur V, Herrington JD, Walker MG "Successful treatment of pegaspargase-induced acute hepatotoxicity with vitamin B complex and L-carnitine" Proc (Bayl Univ Med Cent) 29 (2016): 46-7. [PMID: 26722167]
94	Product Information. Asparlas (calaspargase pegol). Servier, Boston, MA.
95	Product Information. Elspar (asparaginase). Merck & Co, Inc, West Point, PA.
96	Product Information. Erwinaze (asparaginase Erwinia chrysanthemi). EUSA Pharma, Newtown, PA.
97	Product Information. Oncaspar (pegaspargase). Rhone-Poulenc Rorer, Collegeville, PA.
98	Burke PW, Aldoss I, Lunning MA, et.al "High-grade PEGylated asparaginase-related hepatotoxicity occurrence in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not necessarily predict recurrent hepatotoxicity in subsequent cycles." Blood 122 (2013): 2671. [PMID: 29407583]
99	Friedman CI, Huneke AL, Kim MH, Powell J "The effect of ampicillin on oral contraceptive effectiveness." Obstet Gynecol 55 (1980): 33-7. [PMID: 7188714]
100	Kleier DJ, Tucker JE "Oral contraceptive failure secondary to dentally prescribed drugs: fact or fiction?" J Colo Dent Assoc 66 (1987): 5-6. [PMID: 3478352]
101	Silber TJ "Apparent oral contraceptive failure associated with antibiotic administration." J Adolesc Health Care 4 (1983): 287-9. [PMID: 6643209]
102	Xu D, Xiao Y, Pan H, Mei Y. Toxic effects of tetracycline and its degradation products on freshwater green algae.?Ecotoxicol Environ Saf. 2019;174:43-47. [PMID: 30818259]
103	Campbell NR, Hasinoff BB "Iron supplements: a common cause of drug interactions." Br J Clin Pharmacol 31 (1991): 251-5. [PMID: 2054263]
104	Gothoni G, Neuvonen PJ, Mattila M, Hackman R "Iron-tetracycline interaction: effect of time interval between the drugs." Acta Med Scand 191 (1972): 409-11. [PMID: 5031537]
105	Greenberger NJ "Absorption of tetracyclines: interference by iron." Ann Intern Med 74 (1971): 792-3. [PMID: 5559446]
106	Neuvonen PJ, Gothoni G, Hackman R, Bjorksten K "Interference of iron with the absorption of tetracyclines in man." Br Med J 4 (1970): 532-4. [PMID: 5483323]
107	Neuvonen PJ, Penttila O "Effect of oral ferrous sulphate on the half-life of doxycycline in man." Eur J Clin Pharmacol 7 (1974): 361-3. [PMID: 4607747]
108	Product Information. Minocin (minocycline). Lederle Laboratories, Wayne, NJ.
109	Venho VM, Salonen RO, Mattila MJ "Modification of the pharmacokinetics of doxycycline in man by ferrous sulphate or charcoal." Eur J Clin Pharmacol 14 (1978): 277-80. [PMID: 729621]
110	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
111	Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111). GE Healthcare, Princeton, NJ.
112	Product Information. Velphoro (sucroferric oxyhydroxide). Fresenius Medical Care North America, Lexington, MA.
113	Elliott GR "Sodium bicarbonate and oral tetracycline." Clin Pharmacol Ther 13 (1972): 459. [PMID: 5026384]
114	Jaffe JM, Colaizzi JI, Poust RI, McDonald RH Jr "Effect of altered urinary pH on tetracycline and doxycycline excretion in humans." J Pharmacokinet Biopharm 1 (1973): 267-82.
115	Jaffe JM, Poust RI, Feld SL, Colaizzi JL "Influence of repetitive dosing and altered urinary pH on doxycycline excretion in humans." J Pharm Sci 63 (1974): 1256-60. [PMID: 4852448]
116	Product Information. Fosrenol (lanthanum carbonate). Shire US Inc, Florence, KY.
117	Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
118	Product Information. Myfortic (mycophenolic acid). Novartis Pharmaceuticals, East Hanover, NJ.
119	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
120	Product Information. Photofrin (porfimer). Sanofi Winthrop Pharmaceuticals, New York, NY.
121	European Medicines Agency "Summary on compassionate use. Remdesivir Gilead.".
122	Gilead Sciences, Inc "About Remdesivir.".
123	US Food and Drug Administration "Fact sheet for health care providers emergency use authorization (EUA) of remdesivir (GS-5734TM)".
124	Product Information. Auryxia (ferric citrate). Keryx Biopharmaceuticals, Inc., New York, NY.
125	Penttila O, Hurme H, Neuvonen PJ "Effect of zinc sulphate on the absorption of tetracycline and doxycycline in man." Eur J Clin Pharmacol 9 (1975): 131-4. [PMID: 786686]
126	Product Information. Visudyne (verteporfin) Valeant Pharmaceuticals, Costa Mesa, CA.
127	Alexander MR "Tetracycline and rises in urea nitrogen." JAMA 221 (1972): 713-4
128	Jick H, Slone D, Shapiro S, et al "Tetracycline and drug-attributed rises in blood urea nitrogen: a report from the Boston Collaborative Drug Surveillance Program." JAMA 220 (1972): 377-9
129	Friedman H, Greenblatt DJ, LeDuc BW "Impaired absorption of tetracycline by colestipol is not reversed by orange juice." J Clin Pharmacol 29 (1989): 748-51. [PMID: 2778097]
130	Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS "Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia." Drugs 19 (1980): 161-80. [PMID: 6988203]
131	Product Information. Colestid (colestipol HCI). Pharmacia and Upjohn, Kalamazoo, MI.

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence